Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man. - Wikidata - awgldk - TriplyDB

Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man.

Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man.

http://www.wikidata.org/entity/Q41549448

about

Safety of milrinone use in neonatal intensive care units Evaluation of intravenous amrinone: the first of a new class of positive inotropic agents with vasodilator properties.Side effects of amrinone therapy.Clinical experience with amrinone in patients with advanced congestive heart failure.Factors influencing survival and mode of death in severe chronic ischaemic cardiac failure.The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure.The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis.Effects of amrinone on the transmembrane action potential of rabbit sinus node pacemaker cells.Acute heart failure: inotropic agents and their clinical uses.Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate.Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy.Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double blind comparison with placebo Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function The appropriate use of inotropes in shock.Myocardial beta-adrenoceptor function and regulation in heart failure: implications for therapy Is inotropic therapy appropriate for patients with chronic congestive heart failure? Or is the digitalis leaf withering?Inotropic drugs for the treatment of heart failure.Review of intermittent dobutamine infusions for congestive cardiomyopathy.Agents for the treatment of heart failure.Current management of patients after cardiopulmonary bypass.Therapeutic strategies in congestive heart failure and the new inotrope-vasodilator agents.Effects of intracoronary and intravenous amrinone infusions in patients with cardiac failure and patients with near normal cardiac function.Interaction of amrinone with endogenous adenosine in guinea-pig atria.Hemodynamic effects of amrinone in children after cardiac surgery.Alternatives to the digitalis glycosides for heart failure.New Inotropic Agents in the Management of Cardiac Failure.Excitatory and inhibitory actions of amrinone on the guinea-pig isolated ileum and vas deferens.RETRACTED: Different effects of olprinone on contractility in nonfatigued and fatigued diaphragm in dogs

P2860

Q33419080-097D0EC3-A2D0-47CC-844B-2B500EF0E371 Q33458068-3A507744-234B-4E69-8635-4615607CE4F6 Q33482058-DAA8C05D-CE63-4A3D-8998-26567F7282CE Q33484907-4EAF448D-232B-4491-A349-1660E2C74675 Q34117868-BFB787EA-B432-4CBC-8CEF-D50E988E0156 Q34621018-4760F47F-960E-4539-BC05-61A6D41BEE7A Q34776831-07E0EE49-91F7-47F9-96B0-C444013F35EB Q36097995-AF3D29F9-7EA9-497D-A91C-76C080E8EF39 Q36632217-7D2171F0-3535-4D45-9CF0-D8E4977113D5 Q36743146-21FDD6D0-9D91-49E7-AFB7-F1A60B4AAA9C Q36750760-EA6E438A-7155-40F4-BD4E-10494DE46964 Q36755765-580E2D30-4FE2-46BA-9CAC-1539BA07D8CD Q36854792-973F6742-5377-491F-9994-8C6E00ED50CC Q37936637-E9D158FA-7F35-45D3-A4F0-C7CC6E088858 Q38282980-9DE78678-69A7-4ED0-9806-45866E06228A Q38951649-6BC40FF2-1F50-43D0-8F21-1CC583F679A7 Q39405022-0BF2B16C-693A-4120-AD18-71A1FD0A3C44 Q39660139-64A5FCEF-5AE8-4A0D-8351-E562124B0590 Q40091128-4AE9BB7F-AAA6-4A93-9B58-14622BB2792D Q40331316-DD3E7F2C-4DAE-480C-91CA-B9FBF0C4D815 Q40346741-7DFA1923-D7A0-4353-83EC-DA4088A5ED0A Q41309655-6A01D74E-97EE-480A-8ACC-0719C520A0FF Q41837331-82672F73-0D0B-497A-9817-91329A3928BB Q42636446-C74E2252-9E23-4369-B8E2-4971F2075EAE Q44926475-27E621A0-995B-4FAE-8359-8DB4C353A743 Q45812551-FFA36FCE-1E4B-47D8-A7B6-1A526765BE28 Q46404536-59ECA70D-1367-43F7-BEA9-0FFA07ED3692 Q56765618-2E13EED0-3CE5-4C92-9C22-1F62FC4402B0

P2860

Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man.

http://www.wikidata.org/entity/Q41549448

description

1979 nî lūn-bûn

@nan

1979年の論文

@ja

1979年学术文章

@wuu

1979年学术文章

@zh-cn

1979年学术文章

@zh-hans

1979年学术文章

@zh-my

1979年学术文章

@zh-sg

1979年學術文章

@yue

1979年學術文章

@zh

1979年學術文章

@zh-hant

name

Amrinone: a new non-glycosidic ...... ble myocardial failure in man.

@en

type

label

Amrinone: a new non-glycosidic ...... ble myocardial failure in man.

@en

prefLabel

Amrinone: a new non-glycosidic ...... ble myocardial failure in man.

@en

P1433

Q41549448-B94FCD7A-7C17-4006-ABEA-F9498C6631AA

P1476

Q41549448-9D358EAC-4762-4D3C-BF35-A872C71E3EFC

P2093

Q41549448-10DF9D1E-D312-4EAC-B1E3-C2C6FA3D97F1

Q41549448-54580B99-CE98-4CC8-AF88-6236D6A14CF0

Q41549448-6462553D-8AAB-4224-A87D-3728DD16EFD7

Q41549448-6D578A03-7847-4436-9CA8-7541944CF27E

Q41549448-74292923-574F-4D46-B542-4FEE460EC363

Q41549448-758E5C21-B949-4A50-9EC8-55A8051D61D4

Q41549448-D7178D8B-DBB9-4669-BFEA-DDF7B3C3E3A7

Q41549448-EAFAE612-F939-4569-B95D-EDE76223262B

Q41549448-EC585A5D-B8A0-434C-A530-12E757A33E75

P304

Q41549448-5C47FD2B-9BFC-455D-A7AA-8C4B6028E5A2

P31

Q41549448-E79B631B-2C96-4232-9FA0-31797EF4A7D4

P356

Q41549448-4768B46A-A549-4B8D-9C8A-EF395CECF61E

P407

Q41549448-8F1EA377-F693-41E8-A594-6B6B8637E84C

P433

Q41549448-F6AB1EA3-BB29-4A95-9022-82B03BA34525

P478

Q41549448-617EAA66-1C62-4D9C-A334-0B444F0094AA

P577

Q41549448-6FED64E1-C446-4870-92E5-BAC5968C9263

P698

Q41549448-C92401C0-156B-4EA0-B1CF-BC3F49347C82

P356

01.CIR.59.6.1098

P1433

P1476

Amrinone: a new non-glycosidic ...... ble myocardial failure in man.

@en

P2093

Alousi AA

http://www.w3.org/2001/XMLSchema#string

Davis R

http://www.w3.org/2001/XMLSchema#string

Davolos D

http://www.w3.org/2001/XMLSchema#string

Keung E

http://www.w3.org/2001/XMLSchema#string

LeJemtel TH

http://www.w3.org/2001/XMLSchema#string

Matsumoto M

http://www.w3.org/2001/XMLSchema#string

Ribner HS

http://www.w3.org/2001/XMLSchema#string

Schwartz W

http://www.w3.org/2001/XMLSchema#string

Sonnenblick EH

http://www.w3.org/2001/XMLSchema#string

P304

1098-1104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.59.6.1098

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

1979-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

436202

http://www.w3.org/2001/XMLSchema#string